Myokardia Inc (NASDAQ:MYOK) insider Jake Bauer sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total value of $225,000.00. Following the completion of the transaction, the insider now owns 56,777 shares in the company, valued at $2,554,965. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Jake Bauer also recently made the following trade(s):
- On Tuesday, January 2nd, Jake Bauer sold 5,000 shares of Myokardia stock. The shares were sold at an average price of $42.89, for a total value of $214,450.00.
Myokardia Inc (NASDAQ MYOK) opened at $52.90 on Friday. Myokardia Inc has a 52 week low of $10.55 and a 52 week high of $53.25. The company has a market capitalization of $1,772.76, a price-to-earnings ratio of -69.60 and a beta of 4.21.
Myokardia (NASDAQ:MYOK) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) EPS for the quarter, hitting analysts’ consensus estimates of ($0.42). Myokardia had a negative return on equity of 14.92% and a negative net margin of 53.49%. The company had revenue of $5.63 million for the quarter, compared to analysts’ expectations of $6.10 million. During the same period in the prior year, the firm earned ($0.35) earnings per share. The firm’s revenue was up 58.6% compared to the same quarter last year. research analysts forecast that Myokardia Inc will post -1.62 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Myokardia by 11.5% during the second quarter. Vanguard Group Inc. now owns 764,919 shares of the biotechnology company’s stock worth $10,020,000 after purchasing an additional 78,800 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Myokardia by 103.5% during the second quarter. JPMorgan Chase & Co. now owns 476,575 shares of the biotechnology company’s stock worth $6,243,000 after purchasing an additional 242,408 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Myokardia by 2,151.7% during the third quarter. Wells Fargo & Company MN now owns 417,439 shares of the biotechnology company’s stock worth $17,887,000 after purchasing an additional 398,900 shares in the last quarter. VHCP Management II LLC purchased a new stake in shares of Myokardia during the third quarter worth $11,355,000. Finally, RTW Investments LP purchased a new stake in shares of Myokardia during the third quarter worth $10,882,000. Institutional investors own 63.61% of the company’s stock.
MYOK has been the topic of a number of recent analyst reports. Zacks Investment Research cut Myokardia from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Credit Suisse Group reiterated an “outperform” rating and issued a $55.00 price objective (up from $45.00) on shares of Myokardia in a report on Tuesday, September 19th. TheStreet cut Myokardia from a “c” rating to a “d+” rating in a report on Friday, November 3rd. JPMorgan Chase & Co. initiated coverage on Myokardia in a report on Tuesday, December 12th. They issued an “overweight” rating and a $54.00 price objective on the stock. Finally, BidaskClub cut Myokardia from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. Myokardia has an average rating of “Hold” and an average price target of $54.83.
Myokardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.